Oruka Therapeutics, Inc. (ORKA) is a publicly traded company in the Unknown sector. Across all available filings, 7 corporate insiders have executed 19 transactions totaling $214.3K, demonstrating a bearish sentiment with -$214.3K in net insider flow. The most recent transaction on Jan 23, 2026 involved a transaction of 130,000 shares valued at $0.
No significant insider buying has been recorded for ORKA in the recent period.
No significant insider selling has been recorded for ORKA in the recent period.
Based on recent SEC filings, insider sentiment for ORKA is bearish with an Insider Alignment Score of 0/100 and a net flow of -$214.3K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Oruka Therapeutics, Inc. (ORKA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 7 insiders are actively trading ORKA stock, having executed 19 transactions in the past 90 days. The most active insider is Tomas Kiselak (Executive), who has made 2 transactions totaling $11.3M.
Get notified when executives and directors at ORKA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | T. Quinlan Paul | General Counsel | Award | 130,000 | $N/A | $0 | |
| Jan 23, 2026 | T. Quinlan Paul | General Counsel | Award | 32,500 | $N/A | $0 | |
| Jan 23, 2026 | Otto Klein Lawrence | Executive | Award | 306,700 | $N/A | $0 | |
| Jan 23, 2026 | Otto Klein Lawrence | Executive | Award | 76,700 | $N/A | $0 | |
| Jan 23, 2026 | Agarwal Arjun | SVP, Finance | Award | 70,000 | $N/A | $0 | |
| Jan 23, 2026 | Agarwal Arjun | SVP, Finance | Award | 17,500 | $N/A | $0 | |
| Jan 23, 2026 | Lee Sandler Laura | Chief Operating Officer | Award | 130,000 | $N/A | $0 | C-Suite |
| Jan 23, 2026 | Lee Sandler Laura | Chief Operating Officer | Award | 32,500 | $N/A | $0 | C-Suite |
| Jan 23, 2026 | Goncalves Joana | Chief Medical Officer | Award | 130,000 | $N/A | $0 | |
| Jan 23, 2026 | Goncalves Joana | Chief Medical Officer | Award | 32,500 | $N/A | $0 | |
| Jan 23, 2026 | Dambkowski Carl | Executive | Other | 116,483 | $N/A | $0 | |
| Dec 19, 2025 | Goncalves Joana | Executive | Option Exercise | 3,500 | $7.80 | $27.3K | |
| Dec 19, 2025 | Goncalves Joana | Executive | Option Exercise | 3,500 | $6.84 | $23.9K | |
| Dec 19, 2025 | Goncalves Joana | Executive | Sale | 3,080 | $31.58 | $97.3K | |
| Dec 19, 2025 | Goncalves Joana | Executive | Sale | 641 | $28.53 | $18.3K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Award(A) | 12 | $11.3M | 97.7% |
Sale(S) | 4 | $214.3K | 1.8% |
Exercise(M) | 2 | $51.2K | 0.4% |
Other(J) | 1 | $0 | 0.0% |
Insider selling pressure at Oruka Therapeutics, Inc. has increased, with 7 insiders executing 19 transactions across all time. Total sales of $214.3K significantly outpace purchases of $0, resulting in a net outflow of $214.3K. This selling activity appears largely discretionary, which may warrant closer attention from investors.